title: Male hormonal contraceptives: current status and future prospects.
abstract: Because of the shortcomings of currently available methods of male contraception, efforts have been made to develop additional forms of contraception for men. The most promising approach to male contraceptive development involves hormones, and requires the administration of exogenous testosterone. When administered to a healthy man, testosterone functions as a contraceptive by suppressing the secretion of luteinizing hormone and follicle-stimulating hormone from the pituitary, thereby depriving the testes of the signals required for normal spermatogenesis. After 2-3 months of treatment, low levels of pituitary gonadotropins lead to markedly decreased sperm counts and effective contraception in the majority of men. Treatment with exogenous testosterone has proven not to be associated with serious adverse effects and is well tolerated by men. In addition, sperm counts uniformly normalize when testosterone is discontinued. Thus, male hormonal contraception is safe, effective, and reversible; however, spermatogenesis is not suppressed to zero in all men, meaning that some diminished potential for fertility persists. Because of this, recent studies have combined testosterone with progestogens and/or gonadotropin-releasing hormone antagonists to further suppress pituitary gonadotropins and optimize contraceptive efficacy. Current combinations of testosterone and progestogens completely suppress spermatogenesis in 80-90% of men without severe adverse effects, with significant suppression in the remainder of individuals. Recent trials with newer, long-acting forms of injectable testosterone, which can be administered every 8 weeks, combined with progestogens, administered either orally or by long-acting implant, have yielded promising results and may soon result in the marketing of a safe, reversible, and effective hormonal contraceptive for men.
authors.affiliation: Department of Medicine, Center for Research in Reproduction and Contraception, University of Washington, Seattle, Washington 98195, USA. jamory@u.washington.edu
authors.forename: John K
authors.initials: JK
authors.lastname: Amory
mesh_terms: D003267:Contraception / Q000379:methods*; D003272:Contraceptive Agents, Male / Q000008:administration & dosage / Q000494:pharmacology; D004338:Drug Combinations; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008297:Male; D011372:Progestins / Q000008:administration & dosage / Q000494:pharmacology; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects*; D013739:Testosterone / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D003272:Contraceptive Agents, Male; D004338:Drug Combinations; D006727:Hormone Antagonists; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone